Examining the Evolution of Treatment With CDK4/6 Inhibitors in Metastatic Breast Cancer
Anne Favret, MD discusses the FDA approval of capivasertib in combination with fulvestrant for HR-positive, HER2-negative breast cancer.
Anne Favret, MD discusses the FDA approval of capivasertib in combination with fulvestrant for HR-positive, HER2-negative breast cancer.
The FDA has granted priority review to dostarlimab plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer.
Kelly K. Hunt, MD, of The University of Texas MD Anderson Cancer Center, discusses the benefits to patients with neoadjuvant therapy in advanced, inoperable breast…
The PRECEDE study demonstrated the feasibility of a large-scale early detection and prevention program for pancreatic cancer.
Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.
PHILADELPHIA (April 29, 2024) —Following her double mastectomy in October of 2019, Agnes Judge fell into a deep depression – experiencing what she recalls as…
Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses how advancements in precision medicine have improved outcomes for patients with brain metastases.
Dr. Bose discusses his perspective on quality-of-life preservation for his patients with myelofibrosis, including the symptoms that have the most negative impact on patients’ quality…
Hypofractionated IMRT with concurrent chemotherapy appears to be well tolerated as post-operative treatment in patients with cervical cancer.
In this issue of Blood, Leung et al1 present preclinical findings demonstrating the potential of neoantigen-specific T cells to recognize acute myeloid leu
Using a cohort from the Pathways Study, researchers sought to determine the influence of healthy eating habits on risk of heart disease among women treated…